ALK and non-small cell lung carcinoma: Herein, inspired by the work of the Nathanael S. Gray Group at Harvard Medical School [28], we report our study on the design, synthesis, and evaluation of new EGFR/ALK dual-target inhibitors containing sulfoxide and a cyclopropyl group for the treatment of non-small-cell lung cancer.